Menu

Identifying Novel Biocatalyst Candidates via High-throughput Stability Monitoring

NanoTemper Technologies invites you to join them for an educational webinar.

Jul 25, 2018
The Scientist Creative Services Team

Identifying Novel Biocatalyst Candidates via High-throughput Stability Monitoring from thescientistllc on Vimeo.

The stability of enzymatic biocatalysts is of primary importance in the biotechnology, food, chemical, and pharmaceutical industries, but screening for biocatalyst stability has been a long-standing challenge. Native enzymes may not possess the optimal activity required for a specific protein-engineering need, which is why biocatalysts are often modified to withstand different conditions, such as elevated temperatures or the presence of organic co-solvents. In this webinar, sponsored by NanoTemper Technologies, learn about Prometheus, a platform that runs nanoDSF technology and how we are using this system to more efficiently screen biocatalyst candidates by characterizing their stability. We will share how nanoDSF can reveal key information on the stability of these enzymes and assist in more effectively identifying and selecting these target molecules.

Topics to be covered:

  • Identifying and isolating biocatalysts with optimal properties based on their stability
  • Benefits to understanding target molecule stability in selection, optimiziation, and characterization steps
  • Analysis of protein stability using nanoDSF

Meet the Speakers:

Beate Kern, PhD
Product Manager
NanoTemper Technologies



Wolf-Dieter Fessner, PhD
Professor of Organic Chemistry
Technische Universitat
Darmstadt, Germany




January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.